<?xml version="1.0" encoding="UTF-8"?>
<p id="p0015">There are currently no antiviral drugs approved for the treatment of CoV-specific illnesses. Given the rapidly evolving pandemic of COVID-19, it is crucial for public health practitioners and the One Health community to stay up to date on potential therapeutic options that are under investigation [
 <xref rid="bb0095" ref-type="bibr">19</xref>]. Based on existing data, remdesivir is a promising candidate, and multi-site clinical trials of remdesivir are now underway among hospitalized adults with COVID-19 [
 <xref rid="bb0100" ref-type="bibr">20</xref>]. This review summarizes the knowledge to date on remdesivir as a therapeutic option for CoVs.
</p>
